Mohammed A. Mashahit
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mohammed A. Mashahit has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Iman Hamed Bassyouni
Rheumatology and Rehabilitation Department, Faculty of Medicine, Cairo University, Cairo, Egypt
2 shared publications Ehab A. Hassan
1 shared publication- Eman Eltahlawy
Department of Environmental Health and Occupational Medicine, National Research Centre, Cairo, Egypt
1 shared publication Eman M. Ezzat
1 shared publicationG. Hamdy
Cairo University
1 shared publicationG.A. Abd El-Wahab
National Cancer Institute
1 shared publication
Latest Publications
- Open Access
- 10 January 2017
- Published by Sciencedomain International in Asian Journal of Medicine and Health
- Vol. 6 (4) , 1-11
Visfatin Level in Diabetic and Non-diabetic Chronic Kidney Diseases
Introduction: Chronic kidney disease (CKD) has become a global public health threat. The irreversible nature of the disease, its association with significant morbidity and mortality as well as the cost of renal replacement therapy leads to a large burden for health care providers, particularly in developing countries like Egypt. Objective: To find a non-invasive method to evaluate association of serum visfatin with chronic kidney disease secondary to diabetic nephropathy and compare to patients with chronic kidney disease secondary to other causes. Methods: Ninety individuals including 30 healthy controls and 60 patients of CKD were included in this study. Patients with CKD were further grouped based on etiology of CKD into 30 diabetic patients and 30 non-diabetic patients. Patients with type 1 diabetes mellitus, urinary tract infection, urolithiasis, liver cirrhosis, stroke, ischemic heart disease, and rheumatoid arthritis were excluded. Measurement of serum visfatin was done through ELISA Kit (Elabscience pharmaceuticals). Results: Visfatin concentration was significantly high in patients with CKD compared to controls (p < 0 .001). No significant difference in Visfatin concentrations between patients of CKD with and without diabetes was detected (p > 0.05). Visfatin concentration was significantly high in patients with CKD stage 2 compared to CKD stage 1 (p < 0 .001). Conclusion: The present study confirms the association of visfatin with CKD, however further studies at molecular level to check its expression within renal tissue may clarify its definitive role in CKD.
- 10 January 2017
- Published by Sciencedomain International in Asian Journal of Medicine and Health
- Vol. 6 (4) , 1-11
Open AccessVisfatin Level in Diabetic and Non-diabetic Chronic Kidney Diseases
Introduction: Chronic kidney disease (CKD) has become a global public health threat. The irreversible nature of the disease, its association with significant morbidity and mortality as well as the cost of renal replacement therapy leads to a large burden for health care providers, particularly in developing countries like Egypt. Objective: To find a non-invasive method to evaluate association of serum visfatin with chronic kidney disease secondary to diabetic nephropathy and compare to patients with chronic kidney disease secondary to other causes. Methods: Ninety individuals including 30 healthy controls and 60 patients of CKD were included in this study. Patients with CKD were further grouped based on etiology of CKD into 30 diabetic patients and 30 non-diabetic patients. Patients with type 1 diabetes mellitus, urinary tract infection, urolithiasis, liver cirrhosis, stroke, ischemic heart disease, and rheumatoid arthritis were excluded. Measurement of serum visfatin was done through ELISA Kit (Elabscience pharmaceuticals). Results: Visfatin concentration was significantly high in patients with CKD compared to controls (p < 0 .001). No significant difference in Visfatin concentrations between patients of CKD with and without diabetes was detected (p > 0.05). Visfatin concentration was significantly high in patients with CKD stage 2 compared to CKD stage 1 (p < 0 .001). Conclusion: The present study confirms the association of visfatin with CKD, however further studies at molecular level to check its expression within renal tissue may clarify its definitive role in CKD.
- Open Access
- 10 January 2017
- Published by Sciencedomain International in Asian Journal of Medicine and Health
- Vol. 6 (4) , 1-6
Vitamin D and Insulin Resistance in Metabolic Syndrome
Poor vitamin D status is frequently linked with nearly all elements of the metabolic syndrome. There is insufficient evidence of beneficial effect to recommend vitamin D supplementation as a means of improving insulin resistance. The aim of this study was to determine the relation between vitamin D deficiency and insulin resistance in patients with metabolic syndrome. Materials and Methods: Ninety patients with metabolic syndrome received 200,000 IU vitamin D intramuscularly every 4 weeks for 12 weeks. Serum 25-hydroxy vitamin D [25(OH)D], fasting blood sugar, Hb A1c, homeostasis model assessment of insulin resistance(HOMA IR), serum lipid profiles anthropometric factors and blood pressure were assessed before and after intervention. Results: After intervention, Serum 25-hydroxy vitamin D [25(OH)D] concentration increased in all subjects (14.5 ± 2.2 vs. 32 ± 5.5 (P .0001)]. There was a significant decrease of HOMA-IR (3.05 ± 0.34 vs 2.08 ± .25(P=0.003) in patients with vitamin D deficiency before supplementation. In conclusion vitamin D supplementation improve IR in patients with metabolic syndrome with vit D deficiency. So, vitamin D supplementation based on baseline [25(OH)D] is recommended.
- 10 January 2017
- Published by Sciencedomain International in Asian Journal of Medicine and Health
- Vol. 6 (4) , 1-6
Open AccessVitamin D and Insulin Resistance in Metabolic Syndrome
Poor vitamin D status is frequently linked with nearly all elements of the metabolic syndrome. There is insufficient evidence of beneficial effect to recommend vitamin D supplementation as a means of improving insulin resistance. The aim of this study was to determine the relation between vitamin D deficiency and insulin resistance in patients with metabolic syndrome. Materials and Methods: Ninety patients with metabolic syndrome received 200,000 IU vitamin D intramuscularly every 4 weeks for 12 weeks. Serum 25-hydroxy vitamin D [25(OH)D], fasting blood sugar, Hb A1c, homeostasis model assessment of insulin resistance(HOMA IR), serum lipid profiles anthropometric factors and blood pressure were assessed before and after intervention. Results: After intervention, Serum 25-hydroxy vitamin D [25(OH)D] concentration increased in all subjects (14.5 ± 2.2 vs. 32 ± 5.5 (P .0001)]. There was a significant decrease of HOMA-IR (3.05 ± 0.34 vs 2.08 ± .25(P=0.003) in patients with vitamin D deficiency before supplementation. In conclusion vitamin D supplementation improve IR in patients with metabolic syndrome with vit D deficiency. So, vitamin D supplementation based on baseline [25(OH)D] is recommended.
- Open Access
- 1 October 2011
- Published by Elsevier in Journal of Advanced Research
- Vol. 2 (4) , 327-332
Jaccoud’s arthropathy in patients with systemic lupus erythematosus: One centre study
- 1 October 2011
- Published by Elsevier in Journal of Advanced Research
- Vol. 2 (4) , 327-332
Open AccessJaccoud’s arthropathy in patients with systemic lupus erythematosus: One centre study
- 1 May 2008
- Published by Elsevier in Clinical Immunology
- Vol. 127 (2) , 151-157
CD4+CD25+ regulatory T cells (TREG) in Systemic Lupus Erythematosus (SLE) patients: The possible influence of treatment with corticosteroids
- 1 May 2008
- Published by Elsevier in Clinical Immunology
- Vol. 127 (2) , 151-157
CD4+CD25+ regulatory T cells (TREG) in Systemic Lupus Erythematosus (SLE) patients: The possible influence of treatment with corticosteroids